Johnson & Johnson (JNJ.US) pulmonary arterial hypertension drug approved for new indication

智通财经2026/11/05 09:10

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

According to reports from Zhihui Caijing APP, on November 5, the official website of the National Medical Products Administration (NMPA) showed that Johnson & Johnson (JNJ.US)'s macitentan dispersible tablets have been approved for market launch, with the presumed indication being pediatric pulmonary arterial hypertension.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Johnson & Johnson (JNJ.US) pulmonary arterial hypertension drug approved for new indication

You may also like

Crypto prices